1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc.

LTUS
Lotus Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
98,773.00Market Cap
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
0.92
1.79
2.75
3.49
1.28
1.39
2.56
Basic EPS, GAAP
0.09
0.21
0.54
0.6
0.37
0.28
0.06
Free Cash Flow per Basic Share
-0.12
0.24
-0.06
-0.21
0.06
-0.05
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.01
0.23
0.7
1.39
0.91
1.03
2.14
Tangible Book Value per Share
- -
0.52
1.22
0.1
0.15
0.57
3.33
Basic Weighted Avg Shares
20
20
21
21
44
52
28
Sales/Revenue/Turnover
18
36
57
74
56
73
71
Operating Margin (%)
3.34
12.34
19.88
20.42
34.87
29.28
10.69
Depreciation Expense
- -
1
2
1
2
2
2
Net Income, GAAP
2
4
11
13
16
14
2
Effective Tax Rate (%)
- -
- -
- -
- -
2.19
1.5
0.01
Profit Margin (%)
9.98
11.44
19.72
17.33
29.09
19.84
2.45
Working Capital
- -
8
25
5
-5
-4
-7
LT Debt
- -
5
5
6
5
5
5
Total Equity
- -
12
27
45
66
89
99
Return on Invested Capital (%)
- -
53.82
44.81
33.48
29.62
24.62
- -
Return on Capital (%)
- -
91.37
72.37
51.66
46.09
28.8
34.48
Return on Common Equity (%)
- -
- -
118.27
58.47
47.33
30.68
2.98

Capital Structure

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
ST Debt
- -
- -
- -
LT Borrowings
5
5
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
28
Market Capitalization
29
14
11

Working Capital

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
Total Current Assets
5
7
8
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
1
5
6
Inventories
1
1
1
Total Current Liabilities
8
11
14
Payables & Accruals
7
10
13
ST Debt
- -
- -
- -
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
54,213.23%
35.3%
Free Cash Flow
- -
-104.3%
-200.39%
Net Income, GAAP
- -
65.44%
-12.22%
Sales/Revenue/Turnover
- -
37.89%
28.71%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Zhong Yi Liu
Full Time Employees
233
Sector
Financial Services
Industry
Shell Companies
Address
813 Blue Ridge Drive Nashville TN United States of America 37207
IPO Date
Aug 9, 2005
CIK
0001292087
Website
lotuspharmaceuticalsusa.com
Similar Companies
Plum Acquisition Corp. I (PLMI)
Piermont Valley Acquisition Corp. Class A (CMCAF)
Horizon Acquisition Corporation (HZAC)
Cantor Equity Partners I, Inc. Class A Ordinary Shares (CEPO)
Mars Acquisition Corp. (MARXU)
New Vista Acquisition Corp (NVSAW)
Business
Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. (LTUS) operates as a shell company with no significant current operations, previously engaged in the development, manufacture, and sale of pharmaceuticals primarily in the People's Republic of China; its historical product portfolio included prescription medicines such as Maixin-valsartan capsules for hypertension, Muxineye drops for glaucoma, Yipubishan-octreotide Acetate Injection for gastric ulcers, Brimonidine Tartrate to constrict adrenaline receptors, Levofloxacin Lactate as an intravenous anti-bacterial drug, and Nicergoline as an anti-dementia drug, offered in forms including tablets, capsules, granules, eye-drops, and freeze-dried powder injections focused on cerebro-cardiovascular disease, asthma, and diabetes treatments. The company conducts businesses through wholesale and retail segments targeting domestic and overseas markets. Founded in 1996 by Zhong Yi Liu, who serves as CEO, it is headquartered at 813 Blue Ridge Drive, Nashville, Tennessee, with 383 employees and listed on OTCMKTS. In recent developments within the last two years, the company remains in a development stage actively seeking acquisition partners in emerging sectors, reflecting a strategic shift from active pharmaceutical operations to a shell structure available for mergers or reverse takeovers.